Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report

BACKGROUND: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin’s lymphoma. Standard first-line treatment for this aggressive subtype comprises the anti-CD20 antibody rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. If patients receiving such tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurczak, Wojciech, Bryk, Agata Hanna, Mensah, Patrycja, Gałązka, Krystyna, Trofimiuk–Müldner, Małgorzata, Wyrobek, Łukasz, Sawiec, Anna, Skotnicki, Aleksander B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868005/
https://www.ncbi.nlm.nih.gov/pubmed/27178351
http://dx.doi.org/10.1186/s13256-016-0875-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868005/
https://www.ncbi.nlm.nih.gov/pubmed/27178351
http://dx.doi.org/10.1186/s13256-016-0875-x

Ejemplares similares